Analysis of transcriptional regulatory elements of the human CD23 gene

CD23 (FcgammaRII), the low affinity receptor for IgE, is a single chain 45kDa Type II membrane glycoprotein member of the C-type lectin family. The CD23 molecule is a multifunctional receptor/ligand and cytokine, playing a role in antigen presentation, macrophage activation and cell adhesion. There are two distinct isoforms of human CD23, termed CD23a and CD23b, with the only difference being noted in a 6 or 7 amino acid region in the N-terminal cytoplasmic domain of the protein. These isoforms are generated from distinct transcription start sites and differential RNA splicing of the single CD23 gene, located on chromosome 19. CD23a is constitutively and cell type-specifically expressed on B cells, whereas CD23b can be expressed on B cells, monocytes and other cells of haematopoietic lineage when activated by stimuli including IL-4 and IL-13. A large body of evidence suggests that CD23 plays a regulatory role in IgE production, and cross-linking of CD23 at the cell surface with IgE delivers a negative feed-back signal for IgE production and inhibits the release of soluble CD23 (sCD23). Cleaved sCD23 fragments larger than 25kDa are known to promote IgE production. Allergic disease is thought to be due to the dysregulation of CD23/IgE feed-back mechanisms, probably through increased cleavage of CD23 from the cell surface, leading to increased IgE production and release of inflammatory mediators. Soluble CD23 is considerably elevated in atopic and neoplastic individuals, and this sCD23 can originate from either the a or b isoform on B cells or just from the b isoform on other cells of haematopoietic origin. The patterns of CD23 gene expression and functional diversity has led to the assumption that CD23a and b are involved in B cell function and IgE-mediated I immunity, respectively, with divergence in the signalling pathways attributed to the N-terminal amino acid differences. It was of importance and interest, therefore, to study and elucidate those events which lead to the expression of each CD23 isoform and to pin-point these to differences in promoter activation and regulation. In this research, the activation of the promoter region of each CD23 isoform was studied in great detail, and reporter vector construct studies have shown that each isoform promoter is differentially activated by distinct stimuli. The CD23a promoter contains two IL-4 response elements (IL-4RE), an NFKB site, a glucocorticoid response element (GRE), a B-cell-specific activator protein (BSAP) or Pax-5 binding site, and is activated by IL-4 only. The CD23b promoter, on the other hand, contains two IL- 4RE's separated by an NFKB site, two AP-1 binding sites and is stimulated by IL-4, anti-CD40, anti-p. and PMA. Reporter vector constructs containing truncated promoters revealed that IL-4 stimulation of the CD23a promoter requires the presence of the first IL-4RE/STAT-6 site, while successful IL-4 stimulation of the CD23b promoter is dependent on the second IL-4RE/STAT-6 site. The discovery of these differentially regulated isoform promoter regions confirms the theory that CD23a and CD23b are involved in functionally different roles, and it is hypothesised that these include the prevention of plasma cell formation in B cells and IgE negative regulation, respectively

IL-36α Exerts Pro-Inflammatory Effects in the Lungs of Mice

Interleukin (IL-) 36 cytokines (previously designated as novel IL-1 family member cytokines; IL-1F5– IL-1F10) constitute a novel cluster of cytokines structurally and functionally similar to members of the IL-1 cytokine cluster. The effects of IL-36 cytokines in inflammatory lung disorders remains poorly understood. The current study sought to investigate the effects of IL-36α (IL-1F6) and test the hypothesis that IL-36α acts as a pro-inflammatory cytokine in the lung in vivo. Intratracheal instillation of recombinant mouse IL-36α induced neutrophil influx in the lungs of wild-type C57BL/6 mice and IL-1αβ−/− mice in vivo. IL-36α induced neutrophil influx was also associated with increased mRNA expression of neutrophil-specific chemokines CXCL1 and CXCL2 in the lungs of C57BL/6 and IL-1αβ−/− mice in vivo. In addition, intratracheal instillation of IL-36α enhanced mRNA expression of its receptor IL-36R in the lungs of C57BL/6 as well as IL-1αβ−/− mice in vivo. Furthermore, in vitro incubation of CD11c+ cells with IL-36α resulted in the generation of neutrophil-specific chemokines CXCL1, CXCL2 as well as TNFα. IL-36α increased the expression of the co-stimulatory molecule CD40 and enhanced the ability of CD11c+ cells to induce CD4+ T cell proliferation in vitro. Furthermore, stimulation with IL-36α activated NF-κB in a mouse macrophage cell line. These results demonstrate that IL-36α acts as a pro-inflammatory cytokine in the lung without the contribution of IL-1α and IL-1β. The current study describes the pro-inflammatory effects of IL-36α in the lung, demonstrates the functional redundancy of IL-36α with other agonist cytokines in the IL-1 and IL-36 cytokine cluster, and suggests that therapeutic targeting of IL-36 cytokines could be beneficial in inflammatory lung diseases

Requirement for sphingosine kinase 1 in mediating phase 1 of the hypotensive response to anandamide in the anaesthetised mouse

In the isolated rat carotid artery, the endocannabinoid anandamide induces endothelium-dependent relaxation via activation of the enzyme sphingosine kinase (SK). This generates sphingosine-1-phosphate (S1P) which can be released from the cell and activates S1P receptors on the endothelium. In anaesthetised mice, anandamide has a well-characterised triphasic effect on blood pressure but the contribution of SK and S1P receptors in mediating changes in blood pressure has never been studied. Therefore, we assessed this in the current study. The peak hypotensive response to 1 and 10 mg/kg anandamide was measured in control C57BL/6 mice and in mice pretreated with selective inhibitors of SK1 (BML-258, also known as SK1-I) or SK2 ((R)-FTY720 methylether (ROMe), a dual SK1/2 inhibitor (SKi) or an S1P1 receptor antagonist (W146). Vasodilator responses to S1P were also studied in isolated mouse aortic rings. The hypotensive response to anandamide was significantly attenuated by BML-258 but not by ROMe. Antagonising S1P1 receptors with W146 completely blocked the fall in systolic but not diastolic blood pressure in response to anandamide. S1P induced vasodilation in denuded aortic rings was blocked by W146 but caused no vasodilation in endothelium-intact rings. This study provides evidence that the SK1/S1P regulatory-axis is necessary for the rapid hypotension induced by anandamide. Generation of S1P in response to anandamide likely activates S1P1 to reduce total peripheral resistance and lower mean arterial pressure. These findings have important implications in our understanding of the hypotensive and cardiovascular actions of cannabinoids

Changes in IP3 receptor expression and function in aortic smooth muscle of atherosclerotic mice

Peroxynitrite is an endothelium - independent vasodilator which induces relaxation via membrane hyperpolarisation. A ctivation of IP3 receptors triggers opening of potassium channels and hyperpolarisation. Previously we found that relaxation to peroxynitrite was maintained during development of atherosclerosis due to changes in expression of calcium regulatory proteins. In this study we investigated 1) the mechanism of peroxynitrite - induced relaxation in mouse aorta 2) the effect of atherosclerosis on relaxation to peroxynitrite and other vasodilators 3) the effect of atherosclerosis on expression and function of the IP3 receptor. Aortic function was studied using wire myography and atherosclerosis was induced by fat - feeding ApoE - / - mice . Expression of IP3 receptors was studied using Western blotting and immunohistochemistry . Relaxation to peroxynitrite was attenuated by the IP3 antagonists 2 - APB and xestospongin C and also the Kv channel blocker 4 - AP. Atherosclerosis attenuated vasodilation to cromakalim and the AMPK activator A769662 but not peroxynitrite. Relaxation was attenuated to a greater extent by 2 - APB in atherosclerotic aortae despite reduced expression of IP3 receptors. 4 - AP was less effective in 4 month fat fed ApoE - / - mice. Peroxynitrite relaxation involves IP3 - induced calcium release and K V channel activation. This mechanism becomes less important as atherosclerosis develops and relaxation to peroxynitrite may be maintained by increased calcium extrusion

Improving arteriovenous fistula patency : transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation

Creation of an autologous arteriovenous fistula (AVF) for vascular access in haemodialysis is the modality of choice. However neointimal hyperplasia and loss of the luminal compartment result in AVF patency rates of ~60% at 12months. The exact cause of neointimal hyperplasia in the AVF is poorly understood. Vascular trauma has long been associated with hyperplasia. With this in mind in our rabbit model of AVF we simulated cannulation autologous to that undertaken in vascular access procedures and observed significant neointimal hyperplasia as a direct consequence of cannulation. The neointimal hyperplasia was completely inhibited by topical transdermal delivery of the non-steroidal anti-inflammatory (NSAID) diclofenac. In addition to the well documented anti-inflammatory properties we have identified novel anti-proliferative mechanisms demonstrating diclofenac increases AMPK-dependent signalling and reduced expression of the cell cycle protein cyclin D1. In summary prophylactic transdermal delivery of diclofenac to the sight of AVF cannulation prevents adverse neointimal hyperplasic remodelling and potentially offers a novel treatment option that may help prolong AVF patency and flow rates

Improving arteriovenous fistula patency : transdermal delivery of diclofenac reduces cannulation-dependent neointimal hyperplasia via AMPK activation

Creation of an autologous arteriovenous fistula (AVF) for vascular access in haemodialysis is the modality of choice. However neointimal hyperplasia and loss of the luminal compartment result in AVF patency rates of ~60% at 12months. The exact cause of neointimal hyperplasia in the AVF is poorly understood. Vascular trauma has long been associated with hyperplasia. With this in mind in our rabbit model of AVF we simulated cannulation autologous to that undertaken in vascular access procedures and observed significant neointimal hyperplasia as a direct consequence of cannulation. The neointimal hyperplasia was completely inhibited by topical transdermal delivery of the non-steroidal anti-inflammatory (NSAID) diclofenac. In addition to the well documented anti-inflammatory properties we have identified novel anti-proliferative mechanisms demonstrating diclofenac increases AMPK-dependent signalling and reduced expression of the cell cycle protein cyclin D1. In summary prophylactic transdermal delivery of diclofenac to the sight of AVF cannulation prevents adverse neointimal hyperplasic remodelling and potentially offers a novel treatment option that may help prolong AVF patency and flow rates

The hypotensive effect of acute and chronic AMP-activated protein kinase activation in normal and hyperlipidemic mice

AMP-activated protein kinase (AMPK) is present in the arterial wall and is activated in response to cellular stressors that raise AMP relative to ADP/ATP. Activation of AMPK in vivo lowers blood pressure but the influence of hyperlipidemia on this response has not been studied. ApoE-/- mice on high fat diet for 6 weeks and age-matched controls were treated with the AMPK activator, AICAR daily for two weeks. Under anesthesia, the carotid artery was cannulated for blood pressure measurements. Aortic tissue was removed for in vitro functional experiments and AMPK activity was measured in artery homogenates by Western blotting. ApoE-/- mice had significantly raised mean arterial pressure; chronic AICAR treatment normalized this but had no effect in normolipidemic mice, whereas acute administration of AICAR lowered mean arterial pressure in both groups. Chronic AICAR treatment increased phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase in normolipidemic but not ApoE-/- mice. In aortic rings, AMPK activation induced vasodilation and an anticontractile effect, which was attenuated in ApoE-/- mice. This study demonstrates that hyperlipidemia dysregulates the AMPK pathway in the arterial wall but this effect can be reversed by AMPK activation, possibly through improving vessel compliance

Altered vascular smooth muscle function in the ApoE knockout mouse during the progression of atherosclerosis

Objectives: Relaxation of vascular smooth muscle (VSM) requires re-uptake of cytosolic Ca2+ into the sarcoplasmic reticulum (SR) via the Sarco/Endoplasmic Reticulum Ca2+ ATPase (SERCA), or extrusion via the Plasma Membrane Ca2+ ATPase (PMCA) or sodium Ca2+ exchanger (NCX). Peroxynitrite, a reactive species formed in vascular inflammatory diseases, upregulates SERCA activity to induce relaxation but, chronically, can contribute to atherogenesis and altered vascular function by escalating endoplasmic reticulum stress. Our objectives were to determine if peroxynitrite-induced relaxation and Ca2+ handling processes within vascular smooth muscle cells were altered as atherosclerosis develops.<p></p> Methods: Aortae from control and ApoE−/− mice were studied histologically, functionally and for protein expression levels of SERCA and PMCA. Ca2+ responses were assessed in dissociated aortic smooth muscle cells in the presence and absence of extracellular Ca2+.<p></p> Results: Relaxation to peroxynitrite was concentration-dependent and endothelium-independent. The abilities of the SERCA blocker thapsigargin and the PMCA inhibitor carboxyeosin to block this relaxation were altered during fat feeding and plaque progression. SERCA levels were progressively reduced, while PMCA expression was upregulated. In ApoE−/− VSM cells, increases in cytosolic Ca2+ [Ca2+]c in response to SERCA blockade were reduced, while SERCA-independent Ca2+ clearance was faster compared to control.<p></p> Conclusion: As atherosclerosis develops in the ApoE−/− mouse, expression and function of Ca2+ handling proteins are altered. Up-regulation of Ca2+ removal via PMCA may offer a potential compensatory mechanism to help normalise the dysfunctional relaxation observed during disease progression

Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling

Adenosine 5′-monophosphate-activated protein kinase (AMPK) is a pivotal regulator of metabolism at cellular and organismal levels. AMPK also suppresses inflammation. We found that pharmacological activation of AMPK rapidly inhibited the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway in various cells. In vitro kinase assays revealed that AMPK directly phosphorylated two residues (Ser515 and Ser518) within the Src homology 2 domain of JAK1. Activation of AMPK enhanced the interaction between JAK1 and 14-3-3 proteins in cultured vascular endothelial cells and fibroblasts, an effect that required the presence of Ser515 and Ser518 and was abolished in cells lacking AMPK catalytic subunits. Mutation of Ser515 and Ser518 abolished AMPK-mediated inhibition of JAK-STAT signaling stimulated by either the sIL-6Ra/IL-6 complex or the expression of a constitutively active V658F-mutant JAK1 in human fibrosarcoma cells. Clinically used AMPK activators metformin and salicylate enhanced the inhibitory phosphorylation of endogenous JAK1 and inhibited STAT3 phosphorylation in primary vascular endothelial cells. Therefore, our findings reveal a mechanism by which JAK1 function and inflammatory signaling may be suppressed in response to metabolic stress and provide a mechanistic rationale for the investigation of AMPK activators in a range of diseases associated with enhanced activation of the JAK-STAT pathway. 2016</p

Oestrogen receptor alpha in pulmonary hypertension

Aims Pulmonary arterial hypertension (PAH) occurs more frequently in women with mutations in bone morphogenetic protein receptor type 2 (BMPR2) and dysfunctional BMPR2 signalling underpinning heritable PAH. We have previously shown that serotonin can uncover a pulmonary hypertensive phenotype in BMPR2+/− mice and that oestrogen can increase serotinergic signalling in human pulmonary arterial smooth muscle cells (hPASMCs). Hence, here we wished to characterize the expression of oestrogen receptors (ERs) in male and female human pulmonary arteries and have examined the influence of oestrogen and serotonin on BMPR2 and ERα expression. Methods and results: By immunohistochemistry, we showed that ERα, ERβ, and G-protein-coupled receptors are expressed in human pulmonary arteries localizing mainly to the smooth muscle layer which also expresses the serotonin transporter (SERT). Protein expression of ERα protein was higher in female PAH patient hPASMCs compared with male and serotonin also increased the expression of ERα. 17β-estradiol induced proliferation of hPASMCs via ERα activation and this engaged mitogen-activated protein kinase and Akt signalling. Female mice over-expressing SERT (SERT+ mice) develop PH and the ERα antagonist MPP attenuated the development of PH in normoxic and hypoxic female SERT+ mice. The therapeutic effects of MPP were accompanied by increased expression of BMPR2 in mouse lung. Conclusion: ERα is highly expressed in female hPASMCs from PAH patients and mediates oestrogen-induced proliferation of hPASMCs via mitogen-activated protein kinase and Akt signalling. Serotonin can increase ERα expression in hPASMCs and antagonism of ERα reverses serotonin-dependent PH in the mouse and increases BMPR2 expression.</p